F
Funxional Therapeutics
Novel small molecule anti-inflammatory therapies development
About Funxional Therapeutics
Funxional Therapeutics Ltd (FXT) was a privately held, clinical-stage pharmaceutical company based in Cambridge, UK, that focused on developing novel anti-inflammatory therapies. The company was founded in 2005 by Dr. David Grainger, based on intellectual property he and his colleagues developed at Cambridge University. Grainger, who spent 15 years leading a laboratory at the university, served as the Chief Scientific Officer.
The company's primary business was the discovery and development of a new class of anti-inflammatory small molecules called somatotaxins. These molecules exploit a novel pathway acting through the type-2 somatostatin receptor to resolve inflammation, which is disrupted in chronic diseases like asthma, COPD, and rheumatoid arthritis. Their lead product was FX125L, an orally available, once-daily small molecule that had completed Phase I studies and was in Phase II trials at the time of the company's acquisition. The business model was asset-centric, focusing on advancing its lead compounds through clinical trials to prove their value for acquisition by a larger pharmaceutical company.
In July 2012, Boehringer Ingelheim, a leading global pharmaceutical company, acquired the worldwide rights to Funxional Therapeutics' FX125L compound and its entire somatotaxin program. Boehringer Ingelheim took over all further research, development, and commercialization responsibilities, intending to develop the therapy for respiratory diseases such as Asthma and COPD. The acquisition represented a successful exit for Funxional's investors, which included Index Ventures, Novo A/S, and Ventech. Following the sale, Funxional Therapeutics ceased operations.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 24.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotechnology, Spinout, Biotech and Pharma, DT and LS, uk is8 life sciences, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | May 2010 | $12M | $49M | Ventech · Medicxi · Novo Ventures | — |
| SERIES A✓Equity / VC | Jan 2006 | $0 | — | Novo Ventures · Medicxi | — |
Growth signals
Latest recorded traffic for Funxional Therapeutics is 0 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Funxional Therapeutics in the Cambridge ecosystem
The Funxional Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Novo Ventures
Medicxi
Ventech
Other known investors1 additional known investor
University of Cambridge
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Funxional Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Funxional Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









